Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRD Induction Followed by VR Maintenance in High Risk Newly Diagnosed Multiple Myeloma
NCT03641456Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2020
- Primary completion
- Dec 2025
- Modality
- Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Sun Yat-sen University. Primary endpoint: Very Good Partial Response or better at 3 years. Started Sep 2020; status: recruiting.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03641456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03641456.